Stelliam Investment Management’s Elevance Health ELV Stock Holding History

Stelliam Investment Management’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-720,000	Closed	-$90.2M	–	44
2016 Q3	$90.2M	Sell	720,000 -45,000	-6%	-$5.81M	3.02%	11
2016 Q2	$100M	Buy	765,000 +70,000	+10%	+$9.58M	3.48%	8
2016 Q1	$96.6M	Buy	695,000 +132,500	+24%	+$17.7M	2.99%	11
2015 Q4	$78.4M	Buy	+562,500	New	+$77.5M	2.34%	18
2015 Q2	–	Sell	-355,000	Closed	-$54.8M	–	64
2015 Q1	$54.8M	Sell	355,000 -147,500	-29%	-$21M	1.23%	43
2014 Q4	$63.1M	Buy	502,500 +102,500	+26%	+$12.7M	1.46%	29
2014 Q3	$47.8M	Sell	400,000 -295,000	-42%	-$33.8M	1.26%	42
2014 Q2	$74.8M	Buy	695,000 +210,000	+43%	+$21.6M	2%	20
2014 Q1	$48.3M	Buy	485,000 +51,000	+12%	+$4.61M	1.6%	30
2013 Q4	$40.1M	Sell	434,000 -86,000	-17%	-$7.64M	1.63%	34
2013 Q3	$43.5M	Buy	520,000 +80,000	+18%	+$6.86M	2.07%	22
2013 Q2	$36M	Buy	+440,000	New	+$32.9M	1.96%	17

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Stelliam Investment Management's ELV Position: Q4 2016 in Review

Stelliam Investment Management sold out of Elevance Health (ELV) in Q4 2016, closing a stake of 720,000 shares — an estimated $90.2M sold.

Stelliam Investment Management first reported a position in ELV in Q2 2013 and held it in 12 quarters. The position peaked at $100M in Q2 2016. 783 funds tracked by Wall St. Rank hold ELV as of Q4 2016.

Stelliam Investment Management reported no remaining Elevance Health position as of Q4 2016 after selling out during the quarter.
Stelliam Investment Management sold 720,000 Elevance Health shares in Q4 2016, an estimated $90.2M.
Stelliam Investment Management first reported a position in Elevance Health in Q2 2013 and held it in 12 quarters.
Stelliam Investment Management's Elevance Health position peaked at $100M in Q2 2016.
783 funds tracked by Wall St. Rank held Elevance Health as of Q4 2016.

Based on Stelliam Investment Management's 13F filing for Q4 2016, filed 13 Feb 2017.